The m⁶A epitranscriptome: A regulatory nexus linking cellular senescence and oncogenesis.
N⁶-methyladenosine (m⁶A) orchestrates RNA fate decisions through a dynamic interplay of writers, erasers, and readers, modulating splicing, stability, and translation.
APA
Xu Y, Zhou X, et al. (2026). The m⁶A epitranscriptome: A regulatory nexus linking cellular senescence and oncogenesis.. Ageing research reviews, 115, 103032. https://doi.org/10.1016/j.arr.2026.103032
MLA
Xu Y, et al.. "The m⁶A epitranscriptome: A regulatory nexus linking cellular senescence and oncogenesis.." Ageing research reviews, vol. 115, 2026, pp. 103032.
PMID
41580155
Abstract
N⁶-methyladenosine (m⁶A) orchestrates RNA fate decisions through a dynamic interplay of writers, erasers, and readers, modulating splicing, stability, and translation. This review unveils how m⁶A fine-tunes senescence-associated pathways (p53/p21, p16-RB) with cancer-context-dependent duality-either as a tumor suppressor or promoter of progression/resistance. Leveraging single-cell and spatial omics, we dissect m⁶A's spatiotemporal heterogeneity in tumor-immune ecosystems. We consolidate diagnostic/prognostic biomarker advances and critically evaluate emerging therapeutics (small-molecule inhibitors, allosteric modulators, nanodelivery systems), addressing clinical barriers like selectivity and safety. Finally, we propose precision strategies targeting m⁶A-senescence networks for combined anti-cancer/anti-aging interventions.
MeSH Terms
Humans; Cellular Senescence; Carcinogenesis; Adenosine; Animals; Neoplasms; Epigenesis, Genetic; Transcriptome
같은 제1저자의 인용 많은 논문 (5)
- Independent Risk Factors and Nomogram-Based Prediction of Pulmonary Fungal Infection in Lung Cancer Inpatients: A Single-Center Retrospective Study.
- CRISPR-based metabolic screening identifies PLCE1 as a pivotal regulator of oncolytic viral antitumor immunity via tumor immune microenvironment remodeling.
- Design, synthesis of 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole derivatives as potential anticancer agents.
- A Retrospective Comparative Study on the Omission Versus Placement of Chest Drain Following Thoracoscopic Sublobar Resection.
- Budget Impact of Venetoclax for Newly Diagnosed Patients with Acute Myeloid Leukemia Aged ≥ 75 Years or with Comorbidities Precluding Intensive Chemotherapy in the United States.